Singapore Private Equity Backs Concord's Take Off Plans
Niche therapy players, backed by strong technology platforms, continue to attract rich valuations in India, the latest being the Singapore-based private equity firm Quadria Capital's investment in Concord Biotech Ltd, an Indian manufacturer of fermentation based biopharmaceutical APIs [active pharmaceutical ingredients].
You may also be interested in...
Niche active pharmaceutical ingredient (API) players in India continue to attract private equity interest - the latest deal involving Warburg Pincus' acquisition of a minority stake in Laurus Labs for about INR5.50bn ($92m).
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
A senior executive shares insights around how the global logistics provider is preparing to deliver the upcoming COVID-19 vaccines across the world. While the company has prior experience with the "deep frozen" temperatures needed for some candidates, there will still be specific challenges and complexities involved.